

Therapeutic Category	PRODUCT_NAME	GENERIC NAME	LABELER_NAME	Brand or Generic (B/G)	LIST ID (1=1yr 5=5yr)	Rank by Gross Spend (Total Amt Paid) of Drugs that Met Threshold 1= Highest Spend	PERCENT_INCREASE (Over One Yr or Five Yr)	GROSS SPEND (Total Paid Amount)	Specialty (Yes/No)	Appeared on previous list (Year)
Antidepressant	PRISTIQ	desvenlafaxine	WYETH LABORATORIES	B	1	3	19.8%	\$ 434,404.65	N	
					5	18	95.5%			
Neuropathic Pain	LYRICA	pregabalin	PFIZER, INC	B	5	2	88.0%	\$ 3,950,051.96	N	2017
					1	2	19.8%			
Arthritis, Psoriasis, etc	ENBREL SURECLICK	etanercept	AMGEN/IMMUNEX	B	5	5	87.9%	\$ 2,310,662.78	Y	2016, 2017
Smoking Cessation	CHANTIX	varenicline	PFIZER, INC	B	1	9	16.5%	\$ 795,112.96	N	
					5	45	85.1%	\$ 198,043.09		
Bipolar Depression, Schizophrenia	LATUDA	lurasidone	SUNOVION PHARMACEUTICALS, INC.	B	5	6	83.2%	\$ 1,921,765.16	N	2016, 2017
Arthritis, Psoriasis, etc	HUMIRA PEN	adalimumab	ABBVIE INC	B	5	1	77.5%	\$ 6,682,062.65	Y	2016, 2017
ADHD	FOCALIN XR	dexmethylphenidate HCl	NOVARTIS	B	5	3	73.5%	\$ 3,072,521.95	N	2017
Overactive Bladder	VESICARE	solifenacin succinate	ASTELLAS	B	1	5	18.8%	\$ 369,634.69	N	
					5	25	69.1%			
Contraceptive	MEDROXYPROGESTERONE ACETATE INJ 150MG/ML	medroxyprogesterone acetate	PFIZER, INC.	G	5	42	67.1%	\$ 206,214.48	N	N
Diabetes	NOVOLOG FLEXPEN	insulin aspart	NOVO NORDISK, INC.	B	5	4	63.9%	\$ 2,470,844.46	N	2017

* only one formulation hit the 5-year list.

Therapeutic Category	PRODUCT_NAME	GENERIC NAME	LABELER_NAME	Brand or Generic (B/G)	Rank by Net Spend		Specialty (Yes/No)	Appeared on previous list (Year)	Appeared on this year's GROSS COST LIST
					LIST ID (1=1yr 5=5yr)	1= highest net spend that met the threshold			
Antibiotic	VANCOCIN HCL	vancomycin	ANI Pharmaceuticals, Inc	B	5	1	N		
					1	8			
Primary immunodeficiency	HIZENTRA	immune globulin subcutaneous (human), 20%	CSL BEHRING	B	5	6	Y		
Post-Herpetic Neuralgia	LIDODERM	lidocaine	ENDO PHARMACEUTICALS	B	5	2	N		
ADHD	STRATTERA*	atomoxetine	LILLY	B	1	11	N		
					5	3			
Antidepressant	PRISTIQ*	desvenlafaxine	PFIZER U.S.	B	5	9	N		Yes
Arthritis, other	ENBREL SURECLICK	etanercept	AMGEN/IMMUNEX	B	1	10	Y	Y 2016, 2017	Yes
Schizophrenia, Bipolar depression, bipolar disorder	SEROQUEL XR*	quetiapine fumarate	ASTRAZENECA	B	5	6	N		
Arthritis, other	HUMIRA PEN	adalimumab	ABBVIE INC	B	1	6	Y	Y 2016, 2017	Yes
ADHD	METHYLPHENIDATE HCL ER *	methylphenidate HCl	ACTAVIS PHARMA	G	1	1	N		
HIV	ODEFSEY	emtricitabine, rilpivirine, and tenofovir alafenamide	GILEAD	B	1	7	N		

*indicates total includes multiple strengths

Rank = 1 being highest net spend